`
`Thomas Joseph Anchordoquy
`
`Skaggs School of Pharmacy and Pharmaceutical Sciences
`University of Colorado Anschutz Medical Campus
`12850 E. Montview Blvd.
`Aurora, CO 80045
`(303) 724-6113
`e-mail: Tom.Anchordoquy@CUAnschutz.edu
`
`EDUCATION
`
`1989 Ph.D. in Zoology, Univ. of Calif., Davis
`1988 M.A. in Zoology, Univ. of Calif., Davis
`1982 B.S. in Biology, Oregon State University
`
`PROFESSIONAL EXPERIENCE
`
`2011-
`
`2005-11
`
`Professor with tenure, Department of Pharmaceutical Sciences,
`University of Colorado Health Sciences Center, Denver, CO.
`2009-2014 Assistant Director, Graduate Program in Pharmaceutical Sciences
`2008-
`Research Associate Professor, Department of Mechanical and Materials
`Engineering, University of Denver
`Associate Professor with tenure, Department of Pharmaceutical Sciences,
`University of Colorado Health Sciences Center, Denver, CO.
`2005-08 Director, Graduate Program in Pharmaceutical Sciences
`1998-2004 Assistant Professor, Department of Pharmaceutical Sciences, University of
`Colorado Health Sciences Center, Denver, CO.
`1993,95-97 Research Associate, Dr. John Carpenter, School of Pharmacy,
`University of Colorado Health Sciences Center, Denver, CO.
`Research Associate, Dr. Steve Hand, Dept. of EPO Biology,
`University of Colorado, Boulder, CO.
`Visiting Lecturer, Dept. of Zoology, University of California, Davis, CA.
`Research Associate, Dept. of Zoology, University of California, Davis, CA.
`Graduate Research Assistant, Drs. J.H. and L.M. Crowe,
`Dept. of Zoology, University of California, Davis, CA.
`Teacher of Mathematics Stephen Wise Middle School, Los Angeles, CA.
`
`1991-95
`
`1990
`1990
`1985-89
`
`1982-85
`
`PATENT FILINGS
`
`2018 Betker JL, Angle BM, Graner MW, Anchordoquy TJ. “Functionalized Nanoparticle
`Formulations For Oral Drug Delivery”. US PROV Patent App. No. 62/749,765, filed
`10/24/2018. PCT Patent App. filed 10/24/19 No. PCT/US19/57898.
`
`Moderna Ex 1021-p. 1
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`2017 Dow S, Lappin M, Wheat W, Chow L, Regan D, Anchordoquy T. “Compositions and
`Methods for Enhanced Innate Immunity” US Application Serial No. 15/476,723 and
`International Application Serial No. PCT/US17/25557, filed 3/31/17. International
`Publication # WO 2017/173371 A1 published 10-5-17.
`
`
`2016 Betker JL, Anchordoquy TJ. “Lipoplexes Formulated for Catalytic Delivery” U.S.
`National Phase Patent Application No. 15/766,088 Based on PCT Application No.
`PCT/US16/55570. Published 10/11/18
`
`
`2016 Anchordoquy TJ, Pacheco T, Tewari-Singh N, Agarwal R. “Topical Silibinin
`Formulations and Uses Therefor” Application No. PCT/US16/55201 filed 10/2/16.
`Chinese patent Application #201680070089.6, filed 6/8/16
`
`
`2016 Anchordoquy TJ, Gottlieb PA, Michels A, Ostrov D. “Methods of Preventing and
`Treating Autoimmunity” International Application No. PCT/US2016034527 filed
`5/27/16.
`
`
`2013 Harrison G., Agarwal R., Anchordoquy T., Glode M., Pacheco T, Stahmer A. “Topical
`silibinin formulations and uses thereof”. U.S. Patent Application No. 13/852,881
`
`
`2011 Abrams, D, Bunch, R, Stevens, K, Anchordoquy T.J. "Central Administration of Stable
`Formulations of Therapeutic Agents for CNS Conditions" US Patent Application No.
`13/051,950 filed 3/18/2011; Published 3/22/12 under #US 2012/0071432 A1.
`
`
`2010 Abrams, D, Stevens, K, Anchordoquy T.J. "Methods and Compositions for the
`Intracerebroventricular Administration of Felbamate" US Patent Application No.
`61/041,493; serial number 12/935,265 filed 9/28/2010
`
`
`2008 Abrams, D, Bunch, R, Stevens, K, Anchordoquy T.J. "Central Administration of Stable
`Formulations of Therapeutic Agents for CNS Conditions" US Patent Application No.
`12/180,373 filed 7/25/2008; Published 3/12/09 under # US-2009-0069267-A1.
`
`
`2008 Abrams, D, Bunch, R, Stevens, K, Anchordoquy T.J. "Central Administration of Stable
`Formulations of Therapeutic Agents for CNS Conditions" US Patent Application No.
`12/161,149 filed 7/16/2008; Published 8/20/09 under #US 2009-0209480 A1.
`
`
`2008 Abrams, D, Bunch, R, Stevens, K, Anchordoquy T.J. "Central Administration of Stable
`Formulations of Therapeutic Agents for CNS Conditions" PCT Patent Application No.
`PCT/US2008/009109 filed 7/25/08, published 1/29/09 as WO 2009/014762.
`
`
`2007 Abrams, D, Bunch, R, Stevens, K, Anchordoquy T.J. "Central Administration of Stable
`Formulations of Therapeutic Agents for CNS Conditions" PCT Patent Application No.
`PCT/US2007/01201 filed 1/17/07, published 7/26/07 as WO 2007/084541.
`
`
`
`Moderna Ex 1021-p. 2
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`2004 Anchordoquy, T.J., Lengsfeld, C.S., Brinkley, K, Jones, R. "Methods and Apparatus
`Using Electrostatic Atomization to Form Liquid Vesicles" US Patent No. 7,914,714 B2
`issued 3/29/11.
`
`
`1999 Anchordoquy, T. and Allison, D. Provisional Patent Application, "Stabilized Nucleotide-
`Based Products", University Technology Corporation # 9072
`
`2018
`
`2018
`
`
`HONORS AND AWARDS
`
`2009, 10, 18 Top Reviewer, J. Pharm. Sci., American Pharmacists Association
`2008-09
`Excellence in Teaching Award, Pharmacy class of 2012
`2008
`
`Excellence Initiative in Pharmaceutical Technology and Biopharmacy, Ludwig
`
`
`Maximilian University, Munich, Germany
`2003, 04
`Outstanding Reviewer of J. Pharm. Sci., American Pharmacists Association
`2000-01
`Excellence in Teaching Award, Pharmacy class of 2004
`
`PROFESSIONAL SERVICE
`
`2020-
`2019
`2019
`2018
`2018-
`2018
`
`NIH-NANO review panel, standing member
`NIH- Special Emphasis Panel for standing members of study sections
`NIH- Nanotherapeutics/Nanoparticles based cancer drug delivery/ interventions
`NIH-NANO panel review, ad hoc
`Advisory Board, Sci
`NIH Special Emphasis Panel. “Innovative Technologies to Deliver Genome Editing
`Machinery to Disease-relevant Cells and Tissues.” UG3/UH3
`NIH Review Panel. “Platform Delivery Technology for Nucleic Acid Based
`Therapeutics.” SBIR/STTR
`NIH - Social Solutions International’s project with the National Institutes of Health
`(NIH)’s Center for Scientific Review (CSR)
`Editorial Board, TechConnect Briefs
`NIH-GDD panel review, ad hoc
`NIH-Pediatric Devices SBIR panel review, ad hoc
`External Reviewer, graduate program in Pharmaceutical Sciences, Texas Tech
`University Health Sciences Center, Amarillo, TX
`Editorial Board, Pharmaceutics
`Organizing Committee, Mechanisms and Barriers in Nanomedicine Workshop,
`Breckenridge, CO
`Symposium Chair/Co-Organizer, Materials for Gene and Drug Delivery.
`TechConnect/Nanotechnology Conference
`2011-16 NIH-BMBI grant review, Permanent Member
`2010-17 Organizing Committee, Freeze Drying of Pharmaceuticals and Biologicals
`Conference, Garmisch Partenkirchen, Germany and Breckenridge, CO
`2009, 10 AAPS National Biotechnology Conference, Chair; abstract screening, Biotech section
`2009-
`Editorial Board, Therapeutic Delivery
`2009
`NIH grant review panel, Biomaterials and Biointerfaces, ad hoc, 5/09, 9/09
`2009
`NIH-NCI grant review panel, Cancer Nanotechnology 7/09
`
`2018-
`2017
`2017
`2017
`
`2017-
`2016
`
`2014-
`
`Moderna Ex 1021-p. 3
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`NIH-Challenge grant review panel 4, mail-in only
`2009
`2009,10 Executive Committee, Biotech Section, AAPS
`2005-10 Section Editor, Biochimica et Biophysica Acta Biomembranes
`2004-06 AAPS Financial Committee
`2004-07 Chair-elect, Chair, and past chair of AAPS Nucleic Acids Focus group.
`2004
`Chair, AAPS Program Review Team on Mentoring
`2003
`AAPS Strategic Visioning Program Review Team - Student Members
`2003
`Past Chair, AAPS Education Committee
`2002
`Organizer and moderator, graduate student outreach program, “A foot in the door”,
`AAPS annual meeting, Toronto, Canada
`2002-06 Editorial Board, Cell Preservation Technology
`2002
`Organizing Committee, Annual Meeting of the Cryobiology Society, Breckenridge,
`CO
`Editorial Board, Journal of Pharmaceutical Sciences
`2001-
`2001-02 Chairman, AAPS Educational Committee
`2001-02 AAPS Program Coordination Committee
`2001
`Organizer and moderator, Macromolecular Drug Delivery Conference, Breckenridge,
` CO
`Organizer and moderator, graduate student outreach program, "Regulatory Affairs",
`AAPS annual meeting, Indianapolis, IN
`2000-02 Editorial Board, Journal of Pharmaceutical and Biomedical Analysis
`1999
`Moderator, Educational Committee Graduate Student Roundtable, AAPS Annual
`Meeting, New Orleans, LA
`Moderator, Molecular Chaperones and Stability of Macromolecules in Solution
`sessions, Novel Approaches to the Stabilization of Biomaterials Workshop,
`Breckenridge, CO
`Editorial Board, Current Pharmaceutical Biotechnology
`Co-Organizer and Moderator, Stability and Analysis of Biopharmaceuticals Symposia,
`East and West Coast BioPharm Conferences, Boston, MA and San Francisco, CA
`Organizer and Moderator, Macromolecular Drug Delivery Conference, Breckenridge,
`CO
`1999-00 AAPS Education Committee, Biotechnology representative
`1998
`Organizer and Moderator, AAPS Gene Delivery Symposium, AAPS Annual
`
`Meeting, San Francisco, CA
`1998
`Moderator and Speaker, Issues in the Formulation of Biopharmaceuticals, AAPS
`
`Biotechnology Short Course, AAPS Annual Meeting, San Francisco, CA
`1997
`Moderator, Small vs. Large Company Luncheon, AAPS Annual Meeting, Boston,
`
`MA
`1996
`Moderator, Symposium on Drug Delivery, Colorado Biopharmaceutical Conference,
`Breckenridge, CO
`
`1999-
`1999
`
`2000
`
`1999
`
`1999
`
`
`OTHER PROFESSIONAL ACTIVITIES
`
`2018-19 Expert Witness, Actelion Pharmaceuticals vs. Sun Pharmaceutical Industries Civil
`Action # 17-5015
`
`Moderna Ex 1021-p. 4
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`2015
`
`2009
`
`Expert Witness, Agila Specialties Inc. and Mylan Laboratories Limited vs. Cephalon,
`Inc. Case No. IPR2015-00503
`Introductory Compounding Laboratory Training, Professional Compounding Centers
`of America. 2-day course
`Expert Witness, Preliminary Injunction #CGC-06-450694. Protiva vs. Sirna
`Co-Founded Sierra Neuropharmaceuticals
`Co-Founded ProtechSure Inc.
`Expert Witness, Patent Interference #105219. Nektar vs. Quadrant
`
`2007
`2007
`2007
`2004
`
`GRANTS/FUNDING
`
`2019-20 Formulation of Drugs for Intracerebroventricular Administration
`Cerebral Therapeutics
`$80K
`
`
`2019-20 Targeting the untargetable: gaining in vivo control of microglial activation through
`optimized Liposome delivered gene therapy ~ the next generation therapeutic for human clinical
`trials. CNS-Pilot Basic Research Team Awards (Multi-PI with L. Watkins)
`CCTSI, Center for Neuroscience $75 K direct
`
`Anchordoquy, Graner (Multi-PI)
`2019 Equipment Supplement
`NIH/NIGMS 3R01GM129046-02S1 $79K
`
`2018-2022 Exploiting an Endogenous Transcytotic Pathway Anchordoquy, Graner (Multi-PI)
`NIH/NIGMS RO1GM129046
`$320K/yr direct
`
`
`2017 Unique Therapeutic Compounds for GSM (PI Nordeen)
`AIA – State of Colorado
`$200K direct
`
`2017-20 Nucleic Acid-Based Therapies for Blood-Borne Viruses (Multi-PI with Nagel)
`ALSAM Therapeutic Innovations
`$250K/yr direct
`
`2017-19 Using Exosomes to treat Muscular Dystrophy (PI Mallela)
`ADR - SSPPS
`$50K
`
`2015-16 Formulating Cystathionine
`CCTSI
`
`2015-16 Improved formulations (with K. Maclean)
`BDEG TTO
`$150K
`
`2014-2015 Improving Vaccines (with S. Dow)
`CSU Innovation
`$20K
`
`2013-17 Tumor Homing Exosomes (Multi PI with Graner)
`NIH/NIBIB RO1 EB016378
`$250K/yr direct
`
`
`$50K
`
`Moderna Ex 1021-p. 5
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`
`
`
`
`
`
`$79,000 direct/year
`
`2013-15 Improved Intracellular Trafficking (Co-PI with Holian)
`Skaggs Foundation
`$25K/yr direct
`
`2011-16 1 Exploiting Cholesterol Nanodomains to Improve Targeting
`NIH/NIGMS RO1GM093287-01A1 $190,000/yr direct
`
`2011-2014 Treatment of Her-2 Overexpressing Breast Cancer with Targeted Immunoliposomes
`Komen Foundation KG 111128 $60,000/yr direct
`
`2008-13 (Subcontract from NIST – Cicerone) Ambient, Dry State Preservation of Therapeutic
`Macromolecules
`NIH EB006398-01
`
`2008-09 Formulation of Drugs for Intracerebroventricular Administration
`Sierra Neuropharmaceuticals
`$230,000 direct
`
`(Co-I with Winter) Visiting Professor Program
`2008
`University of Munich
`
`$135,000 direct
`
`2007-08 (Co-I with Glode) Formulation of Silibinin as a Topical Agent
`NIH-SBIR R41CA171013
`$37,133 direct
`
`2007-08 (Co-I with Stevens)
`Development of Drug Formulations for Intracerebral Administration
`State of Colorado Tech. Dev.
`$200,000 direct
`
`2008-09 Degradation of DNA on Gold and Stability Improvement
`Pfizer Contract
`
`
`
`$40,000 direct
`
`2008-10 Degradation of DNA on Gold and Stability Improvement
`Pfizer Gift
`
`
`
`
`$100,000 direct
`
`2006-11 Formulation of Synthetic Vectors as Lyophilized Products
`NIH-NIBIB 5 RO1 EB005476-02
`
`$640,000 direct
`
`2005-08 Improved Synthetic Vectors by Electrostatic Co-Extrusion
`NSF BES-0433811
`
`
`
`$172,434 direct
`
`2006 A New Treatment for Ineffectively Treated Schizophrenia Patients
`CUTTO
`
`
`
`
`$25,000 direct
`
`2003 Lyophilization of Human Lung Surfactant
`Discovery Labs Inc.
`
`
`
`$49,140
`
`(Co-PI with J. Carpenter)
`2003
`The Effects of Metal Contaminants on Macromolecular Stability
`Ferro-Pfanstiehl
`
`
`
`$50,000
`
`Moderna Ex 1021-p. 6
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`
`(Co-PI with J. Thompson and others)
`2003
`Acquisition of an ion trap mass spectrometer - Equipment grant
`NSF-MRI 0321301
`
`
`
`$137,334
`
`2002-05 Circumventing Plasmid Shear-Induced Degradation
`NSF BES-0239940
`
`$60,000
`
`2001 Stabilization and Characterization of Nonviral, Plasmid-based Therapeutics.
`Valentis, Inc.
`
`
`
`$50,000
`
`
`2000 Stabilization and Characterization of Nonviral, Plasmid-based Therapeutics.
`Valentis, Inc.
`
`
`
`$50,000
`
`Lyophilization of Nonviral Gene Delivery Systems
`2000-03
`NIH NIGMS 1 RO1 GM60587-01 $523,539
`
`(Co-PI with T. Randolph and others)
`2000
`Particle Characterization - Equipment grant
`NSF CTS 0079612
`
`
`
`
`1999 Stabilization and Characterization of Nonviral, Plasmid-based Therapeutics.
`Valentis, Inc.
`
`
`
`$50,000
`
`
`PUBLICATIONS – papers
`
`$192,500
`
`
`Betker JL, Anchordoquy TJ. The Use of Lactose as an Alternative Coating for Nanoparticles.
`J. Pharm. Sci. in press (2020)
`
`Betker JL, Angle BM, Graner MW, Anchordoquy TJ. The Potential of Exosomes from Cow
`Milk for Oral Delivery. J. Pharm. Sci. 108:1496-1505 (2019). Featured Article for April issue.
`
`Fete MG, Betker JL, Shoemaker RK, Anchordoquy TJ. A Novel Method for Conjugating the
`Terminal Amine of Peptide Ligands to Cholesterol: Synthesis iRGD-Cholesterol. Ther. Del. 10
`(1): 11-20 (2019).
`
`Betker JL, Jones D, Childs CR, Helm KM, Terrell K, Nagel MA, Anchordoquy TJ.
`Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery. J. Cont. Rel.
`286:85-93 (2018).
`
`Oushy S*, Hellwinkel JE*, Wang M*, Nguyen GJ, Gunaydin D, Harland TA, Anchordoquy TJ,
`Graner MW. Glioblastoma multiforme-derived extracellular vesicles drive normal astrocytes
`towards a tumour-enhancing phenotype. Phil Trans Roy Soc B, Biol Sci. 2018 Jan 5;373(1737).
`pii: 20160477. doi: 10.1098/rstb.2016.0477. PMID: 29158308 (* equal contributions)
`
`Moderna Ex 1021-p. 7
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`
`Anchordoquy TJ and Simberg D. Watching the Gorilla and Questioning Delivery Dogma. J.
`Cont. Release 262:87-90 (2017).
`
`Anchordoquy TJ, Barenholz Y, Boraschi D, Chorny M, Decuzzi P, Dobrovolskaia M,
`Farhangrazi S, Farrell D, Gabizon A, Ghandehari H, Godin B, La-Beck N, Ljubimova J,
`Moghimi SM, Pagliaro L, Park J-H, Peer D, Ruoslahti, E, Serkova N, Simberg D. Mechanisms
`and Barriers in Cancer Nanomedicine: addressing challenges, looking for solutions ACS Nano
`11(1):12-18 (2017) doi: 10.1021/acsnano.6b08244.
`
`Betker JL, Anchordoquy TJ. Non-Additive Effects of Repetitive Administration of Lipoplexes
`in Immunocompetent Mice. J. Pharm. Sci. 106(3):872-881 (2017) doi:
`10.1016/j.xphs.2016.11.013
`
`Betker JL, Anchordoquy TJ. Effect of a Nude Mouse Model on Nanoparticle-Mediated Gene
`Delivery. Drug Deliv. and Transl. Res. 7: 162-7. doi:10.1007/s13346-016-0327-6 (2017)
`
`Graner AN, Hellwinkel JE, Lencioni AM, Madsen HJ, Harland TA, Marchando P, Nguyen GJ,
`Wang M, Russell LM, Bemis LT, Anchordoquy TJ, Graner MW. HSP90 inhibitors in the
`context of heat shock and the unfolded protein response: effects on a primary canine pulmonary
`adenocarcinoma cell line. Int J Hyperthermia. 2016 Nov 9:1-15.
`http://dx.doi.org/10.1080/02656736.2016.1256503
`
`Redzic JS, Gomez JD, Hellwinkel JE, Anchordoquy TJ, Graner MW. Proteomic analyses of
`brain tumor cell lines amidst the unfolded protein response. Oncotarget 7(30):47831-47847
`(2016). doi: 10.18632/oncotarget.10032.
`
`Hellwinkel JE, Redzic JS, Harland TA, Gunaydin D, Anchordoquy TJ, Graner MW. Glioma-
`derived extracellular vesicles selectively suppress immune responses. Neuro-Oncology
`18(4):497-506 (2016) doi:10.1093/neuonc/nov170
`
`Betker JL, Anchordoquy TJ. Effect of charge ratio on lipoplex-mediated gene delivery and liver
`toxicity. Therapeutic Delivery 6 (11): 1243-1253 (2015) doi:10.4155/tde.15.77.
`
`Kullberg M, Martinson H, Mann K, Anchordoquy TJ. Complement C3 Mediated Targeting of
`Liposomes to Granulocytic Myeloid Derived Suppressor Cells. Nanomedicine 11(6):1355-63
`(2015). doi: 10.1016/j.nano.2015.03.010. PMID: 25839391doi: 10.1016/j.nano.2015.03.010.
`
`Pozzi D, Caracciolo G, Capriotti AL, Cavaliere C, La Barbera G, Anchordoquy TJ, Laganà A.
`Surface chemistry and serum type both determine the nanoparticle-protein corona. J. Proteomics
`119: 209-217 (2015).
`
`Smyth T, Kullberg M, Malik N, Smith-Jones P, Graner MW, Anchordoquy TJ. Biodistribution
`and Delivery Efficiency of Unmodified Tumor-Derived Exosomes. J. Cont. Release 199:145-
`155 (2015).
`
`
`Moderna Ex 1021-p. 8
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`Betker JL, Anchordoquy TJ. Relating Toxicity to Transfection: Using Sphingosine to Maintain
`Prolonged Expression In Vitro. Mol. Pharm. 12:264-73 (2015) PMID: 25418523 PMCID#
`PMC4291780
`
`Smyth, T, Petrova, K, Payton, N, Persaud, I, Redzic, J, Graner, M, Smith-Jones, P,
`Anchordoquy, T. Surface Functionalization of Exosomes Using Click Chemistry. Bioconjugate
`Chemistry 25(10):1777-84 (2014). doi: 10.1021/bc500291r. PMID: 25220352; PMCID#
`PMC4198107
`
`Verhoef, JJF, Carpenter, JF, Anchordoquy, TJ, and Schellekens, H. Potential induction of anti-
`PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discovery
`Today Dec;19(12):1945-52 (2014) DOI: 10.1016/j.drudis.2014.08.015
`
`Payton, NM, Wempe MF, Xu Y, Anchordoquy TJ. Long Term Storage of Lyophilized
`Liposomal Formulations. J. Pharm. Sci. 103:3869–3878 (2014).
`
`
`
`Smyth TJ, Redzic JS, Graner MW, and Anchordoquy TJ. Examination of the specificity of
`tumor cell derived exosomes with tumor cells in vitro. Biochim. Biophys. Acta 1838:2954-65
`(2014)
`
`Kullberg M, McCarthy R., and Anchordoquy TJ. Gene delivery to Her-2+ breast cancer cells
`using a two-component delivery system to achieve specificity. Nanomedicine 10(6):1253-62
`(2014).
`
`Verhoef JJF and Anchordoquy TJ. Questioning the Use of PEGylation for Drug Delivery. Drug
`Delivery and Translational Res. 3:499-503 (2013).
`
`Kullberg, M, McCarthy R, Anchordoquy TJ. Systemic Tumor-Specific Gene Delivery. J. Cont.
`Rel. 172:730-6 (2013)
`
`Betker JL, Gomez J, and Anchordoquy TJ. The effects of lipoplex formulation variables on the
`protein corona and comparisons with in vitro transfection efficiency. J. Cont. Rel. 171:261-268
`(2013).
`
`Payton NM, Wempe MF, Betker JL, Randolph TW, Anchordoquy TJ. Lyophilization of a triply
`unsaturated phospholipid: Effects of trace metal contaminants. Eur. J. Pharm. Biopharm.
`85:306-313 (2013).
`
`Betker JL, Kullberg M, Gomez J, Anchordoquy TJ. Cholesterol domains enhance transfection.
`Therapeutic Delivery 4(4):453-62 (2013).
`
`Epple LM, Griffiths SG, Dechkovskaia AM, White J, Anchordoquy TJ, Bemis LT, Graner
`MW. Medulloblastoma Exosome Proteomics Yield Functional Roles for Extracellular Vesicles
`PLoS ONE 7(7):e42064. Epub 2012 Jul 27 (2012).
`
`
`Moderna Ex 1021-p. 9
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`Kullberg M, Mann K, Anchordoquy TJ. Her-2+ Breast Cancer Cells with Bleomycin
`Immunoliposomes Linked to LLO. Mol. Pharm. 9:2000-2008 (2012).
`
`Xu L, Betker J, Yin H, Anchordoquy TJ. Ligands located within a cholesterol domain enhance
`gene delivery to the target tissue. J. Cont. Release 160:57-63 (2012)
`
`Betker J, Smyth TS, Wang W, Anchordoquy TJ. Application of a UPLC Method in the
`Determination of DNA Quality and Stability J. Pharm. Sci. 101:987-997 (2012).
`
`Smyth TS, Betker J, Wang W, Anchordoquy TJ. Moisture Content Impacts the Stability of
`DNA Adsorbed onto Gold Microparticles. J. Pharm. Sci. 100:4845-4854 (2011).
`
`Lengsfeld CS, Worden L, Lentz YK, Anchordoquy, TJ. Hydrodynamic Degradation Controlled
`by Kolomogorov Length Scales in Pipe Flow. J. Pharm. Sci. 100:3088-3095 (2011).
`
`Xu L, Wempe MF, and Anchordoquy TJ. The effect of cholesterol domains on PEGylated
`liposomal gene delivery in vitro. Therapeutic Delivery 2:451-60 (2011).
`
`Zeles-Hahn MG, Lentz YK, Anchordoquy TJ, Lengsfeld CS. Effect of electrostatic spray on
`human pulmonary epithelial cells. Journal of Electrostatics 69:67-77 (2011).
`
`Anchordoquy TJ. Report on the Freeze-Drying of Pharmaceuticals and Biologicals
`Conference. Therapeutic Delivery 2: 15-17 (2011).
`
`
`Xu L, and Anchordoquy TJ. Drug Delivery Trends in Clinical Trials and Translational
`Medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J.
`Pharm. Sci. 100:38-52 (2011).
`
`Xu L and Anchordoquy TJ. Cholesterol nanodomains: helpers in gene delivery. News and
`Analysis. Therapeutic Delivery 1(3): 365 (2010).
`
`Xu L and Anchordoquy TJ. Effect of cholesterol nanodomains on the targeting of lipid-based
`gene delivery in cultured cells. Molecular Pharmaceutics 7 (4):1311-17 (2010).
`
`Yu, J, and Anchordoquy TJ. Effects of Moisture Content on the Storage Stability of Dried
`Lipoplex Formulations. J. Pharm. Sci., 98(9):3378-89 (2009).
`
`Anchordoquy, TJ, Molina, MdC, and Kempner, ES. A radiation target method for size
`determination of supercoiled plasmid DNA. Analytical Biochemistry, 385:229-233 (2009).
`
`Yu, J, and Anchordoquy TJ. Synergistic Effects of Surfactants and Sugars on Lipoplex
`Stability During Freeze-drying and Rehydration. J. Pharm. Sci., 98(9):3319-28 (2009).
`
`Zillies, JC, Zwiorek, K, Hoffmann, F, Vollmar, A, Anchordoquy, TJ, Winter, G, Coester, C.
`Formulation Development of Freeze-Dried Oligonucleotide-Loaded Gelatin Nanoparticles.
`European Journal of Pharmaceutics and Biopharmaceutics 70:514-5221 (2008).
`
`Moderna Ex 1021-p. 10
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`
`Santoni, BG, Turner, AS, Wheeler, DL, Nicholas, RW, Anchordoquy, TJ, Ehrhart, N. Gene
`Therapy to Enhance Allograft Incorporation after Tissue Irradiation. Clin. Orthop. Relate. Res.,
`466(8):1921-9 (2008).
`
`Xu, L and Anchordoquy, TJ. Cholesterol Domains in Cationic Lipid/DNA Complexes Improve
`Transfection. Biochimica et Biophysica Acta Biomembranes, 1778 (10):2177-81 (2008).
`
`Molina, MdC and Anchordoquy, TJ. Formulation Strategies to Minimize Oxidative Damage in
`Lyophilized Lipid/DNA Complexes during Storage. J. Pharm. Sci., 97(12):5089-5105 (2008).
`
`Molina, MdC and Anchordoquy, TJ. Degradation of Lyophilized Lipid/DNA Complexes
`During Storage: The Role of Lipid and Reactive Oxygen Species. Biochimica et Biophysica
`Acta Biomembranes, 1778(10):2119-26 (2008).
`
`Abrams, DJ, Zheng, L, Choo, KS, Yang, JJ, Wei, W, Anchordoquy, TJ, Zawia, NH, Stevens,
`KE. An Initial Animal Proof-of-Concept Study for Central Administration of Clozapine to
`Schizophrenia Patients. Schizophrenia Research, 100(1-3): 86-96 (2008).
`
`Zhang, Y, Bradshaw-Pierce, EL, DeLille, A, Gustafson, DL, and Anchordoquy, TJ. In vivo
`comparative study of Lipid/DNA complexes with different in vitro serum stability: effects on
`biodistribution and tumor accumulation. J. Pharm. Sci., 97: 237-50 (2008).
`Anchordoquy, TJ, and Molina, MdC. Preservation of DNA. Cell Preservation Technology 5:
`180-188 (2007).
`Molina, MdC and Anchordoquy, TJ. Metal Contaminants Promote Degradation of Lipid/DNA
`Complexes during Lyophilization. Biochimica et Biophysica Acta Biomembranes 1768(3): 669-
`77 (2007).
`Lentz, YK, Anchordoquy, TJ, and Lengsfeld CS. Rationale for the Selection of an Aerosol
`Delivery System for Gene Delivery. Journal of Aerosol Medicine 19 (3): 372-384 (2006)
`
`Patel, MM and Anchordoquy, TJ. Ability of Spermine to Differentiate between DNA
`Sequences – Preferential Stabilization of A-Tracts. Biophysical Chemistry 122: 5-15 (2006).
`
`Lentz, YK, Anchordoquy, TJ, and Lengsfeld, CS. DNA acts as a nucleation site for transient
`cavitation in the ultrasonic nebulizer. J. Pharm. Sci. 95: 607-619 (2006).
`
`Lentz, YK, Worden, LR, Anchordoquy, TJ, and Lengsfeld, CS. Effect of Jet Nebulization on
`DNA: Identifying the Dominant Degradation Mechanism and Mitigation Methods. J. Aerosol
`Sci. 36(8): 973-990 (2005).
`
`Anchordoquy, TJ, Armstrong, TK, and Molina, MdC. Low Molecular Weight Dextrans
`Stabilize Nonviral Vectors during Lyophilization at Low Osmolalities: Concentrating
`Suspensions by Rehydration to Reduced Volumes. J. Pharm. Sci. 94:1226-1236 (2005).
`
`
`Moderna Ex 1021-p. 11
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`Patel, M.M. and Anchordoquy, T.J. The Contribution of Hydrophobicity to the
`Thermodynamics of Ligand-DNA Binding and DNA Collapse. Biophysical Journal 88:2089-
`2103 (2005).
`
`Armstrong, TK and Anchordoquy, TJ. Immobilization of Nonviral Vectors during the Freezing
`Step of Lyophilization. J. Pharm. Sci. 93:2698-2709 (2004).
`
`Patel, MM, Manning, MC, Randolph, TW, and Anchordoquy, TJ. Polymeric Microspheres in
`Gene Delivery: Determination of Polymer Degradation and its Influence on the Mechanism of
`DNA Release. J. Pharm. Sci. 93:2573-2584 (2004).
`
`Molina, MdC, Armstrong TK, Zhang, Y, Patel, MM, Lentz, YK, and Anchordoquy, TJ. The
`Stability of Lyophilized Lipid/DNA Complexes during Prolonged Storage. J. Pharm. Sci.
`93:2259-2273 (2004).
`
`Zhang, Y and Anchordoquy, TJ. The Role of Lipid Charge Density in the Serum Stability of
`Cationic Lipid/DNA Complexes. Biochimica et Biophysica Acta Biomembranes 1663:143-157
`(2004).
`
`Bai, SJ, Katayama, DS, Chou, DKC, Anchordoquy, TJ, Nayar, R, and Manning, MC. High
`throughput formulation of biopharmaceutical products in the postgenomic era. American
`Biotechnology Laboratory 21(11): 28F-28H (2003).
`
`Zhang, Y, Garzon-Rodriguez, W, Manning, MC, and Anchordoquy, TJ. The use of
`fluorescence energy transfer to monitor dynamic changes of lipid-DNA interactions during
`lipoplex formation. Biochimica et Biophysica Acta 1614:182-192 (2003).
`
`Choosakoonkriang, S, Wiethoff, CM, Koe, GS, Smith, JG, Anchordoquy, TJ, and Middaugh,
`CR. An infrared spectroscopic study of the effect of hydration on cationic lipid/DNA
`complexes. J. Pharm. Sci. 92(1): 115-130 (2003).
`
`Armstrong, TC, Girouard, LG, and Anchordoquy, TJ. Effects of PEGylation on the
`preservation of cationic lipid/DNA complexes during freeze-thawing and lyophilization. J.
`Pharm. Sci. 91: 2549-2558 (2002).
`
`Pikal-Cleland, KA, Cleland, JL, Anchordoquy, TJ, and Carpenter, JF. Effect of glycine on pH
`changes and protein stability during freeze-thawing in phosphate buffer systems. J. Pharm. Sci.
`91:1969-1979 (2002).
`
`Lengsfeld, CS, and Anchordoquy, TJ. Shear-induced degradation of plasmid DNA. (invited
`minireview) J. Pharm. Sci. 91:1581-1589 (2002).
`
`Anchordoquy, TJ. Physical stabilization of DNA-based therapeutics during freezing and drying.
`(invited review) American Pharmaceutical Review 4:34-41 (2001).
`
`
`Moderna Ex 1021-p. 12
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`Molina, MdC, Allison, SD, Anchordoquy, TJ. Maintenance of particle size during the freezing
`step of the lyophilization process is insufficient for preservation of activity: insight from other
`structural indicators. J. Pharm. Sci. 90 (8): 1445-1455 (2001).
`
`Anchordoquy, TJ, Izutsu, K-I., Randolph, TW, and Carpenter, JF. Maintenance of quaternary
`structure in the frozen state stabilizes lactate dehydrogenase during freeze-drying. Arch.
`Biochem. Biophys. 390 (1): 35-41 (2001).
`
`Anchordoquy, TJ, Allison, SD, Molina, MdC, Girouard, LG and Carson, TK. Physical
`Stabilization of DNA-based Therapeutics. Drug Discovery Today 6 (9): 441-448 (2001).
`
`Choosakoonkriang, S, Wiethoff, CM, Anchordoquy, TJ, Koe, GS, Smith, JG, and Middaugh,
`CR. Infrared spectroscopic characterization of the interaction of cationic lipids with plasmid
`DNA. J. Biol. Chem. 276 (11):8037-8043 (2001).
`
`Lee, H, Williams, KR, Allison, SD, and Anchordoquy, TJ. Analysis of self-assembled cationic
`lipid-DNA gene carrier complexes using flow field-flow fractionation and light scattering. Anal.
`Chem. 73(4):837-843 (2001).
`
`Allison, SD, Molina, MdC, and Anchordoquy, TJ. Stabilization of lipid/DNA complexes
`during the freezing step of the lyophilization process: the particle isolation hypothesis. Biochim.
`Biophys. Acta. 1468:127-138 (2000).
`
`Allison, SD, and Anchordoquy, TJ. Mechanisms of protection of cationic lipid-DNA
`complexes during lyophilization. J. Pharm. Sci. 89:682-691 (2000).
`
`Anchordoquy, TJ and Koe, GS. Physical stability of nonviral plasmid-based therapeutics.
`(invited review) J. Pharm. Sci. 89:289-296 (2000).
`
`Logan, BA, Anchordoquy, TJ, Monson, RK, and Pan, RS. The effect of isoprene on the
`properties of spinach thylakoids and phosphatidylcholine liposomes. Plant Biology 1: 602-606
`(1999).
`
`Anchordoquy, TJ. Physical characterization of nonviral gene delivery systems. (invited review)
`BioPharm, 12 (9): 46-51 (1999).
`
`Anchordoquy, TJ. Macromolecular Drug Delivery. IDrugs, 2(10): 1005-1008 (1999) - non-
`refereed review.
`
`Anchordoquy, TJ. Physical stability of nonviral gene delivery systems. (invited review)
`BioPharm, 12 (6): 42-48 (1999).
`
`Anchordoquy, TJ, Girouard, LG, Carpenter, JF, and Kroll, DJ. Stability of lipid/DNA during
`agitation and freeze-thawing. J. Pharm. Sci. 87(9): 1046-1051 (1998).
`
`
`Moderna Ex 1021-p. 13
`Moderna v Arbutus
`IPR2019-00554
`
`
`
`Anchordoquy, TJ, Carpenter, JF, and Kroll, DJ. Maintenance of transfection rates and physical
`characterization of lipid/DNA complexes after freeze-drying and rehydration. Arch. Biochem.
`Biophys. 348:199-206 (1997).
`
`Anchordoquy, TJ and Carpenter, JF. Polymers protect lactate dehydrogenase during freeze-
`drying by inhibiting dissociation in the frozen state. Arch. Biochem. Biophys. 332: 231-238
`(1996).
`
`Hardewig, I, Anchordoguy, TJ, Crawford, DL, and Hand SC. Profiles of nuclear and
`mitochondrial encoded mRNAs in developing and quiescent embryos of Artemia franciscana.
`Mol. Cell. Biochem. 158:139-147 (1996).
`
`
`Anchordoguy, TJ, Crawford, DL, Hardewig, I, and Hand, SC. Heterogeneity of DNA binding
`to membranes used in quantitative dot blots. Biotechniques 20:754-756 (1996).
`
`Anchordoguy, TJ and Hand, SC. Reactivation of ubiquitination in Artemia franciscana
`embryos during recovery from anoxia-induced quiescence. J. Exp. Biol. 198:1299-1305 (1995).
`
`Anchordoguy, TJ and Hand, SC. Acute blockage of the ubiquitin-mediated proteolytic pathway
`during invertebrate quiescence. Am. J. Physiol. 267:R895-R900 (1994).
`
`Anchordoguy, TJ, Hofmann, GE, and Hand, SC. Extension of enzyme half-life in quiescent
`Artemia embryos. Am. J. Physiol. 264:R85-R89 (1993).
`
`Drobnis, EZ, Crowe, LM, Berger, T, Anchordoguy, TJ, Overstreet, JW, and Crowe, JH. Cold
`shock damage is due to lipid phase transitions in cell membranes: a demonstration using sperm
`as a model. J. Exp. Zool. 265:432-437 (1993).
`
`Anchordoguy, TJ, Carpenter, JF, Crowe, JH, and Crowe, LM. Temperature dependent
`perturbation of phospholipid bilayers by dimethylsulfoxide. Biochim. Biophys. Acta 1104:117-
`122 (1992).
`
`Anchordoguy, TJ, Cecchini, CA, Crowe, JH, and Crowe, LM. Insights into the cryoprotective
`mechanism of DMSO on phospholipid bilayers Cryobiology 28:467-473 (1991).
`
`Anchordoguy, TJ, Carpenter, JF, Cecchini, CA, Crowe, JH, and Crowe, LM. Effects of protein
`perturbants on phospholipid bilayers. Arch. Biochem. Biophys. 283:356-361 (1990).
`
`Crowe, JH, Carpenter, JF, Crowe, LM, and Anchordoguy, TJ. Are freezing and dehydration
`similar stress vectors? A comparison of modes of interaction of stabilizing solutes with
`biomolecules Cryobiology 27: 219-231 (1990).
`
`Loomis, SH, Carpenter, JF, Anchordoguy, TJ, Crowe, JH, and Branchini,